This site uses cookies to ensure the best viewing experience for our readers.
Liver Treatment Company Galmed Looking to Raise $75 Million in Public Offering

Brief

Liver Treatment Company Galmed Looking to Raise $75 Million in Public Offering

Galmed listed on Nasdaq in 2014. The company's stock jumped around 125% over the past two weeks following a successful study

Dror Reich | 10:45  20.06.2018

Nasdaq-listed Galmed Pharmaceuticals Ltd. is looking to raise $75 million in an underwritten offering of public shares, the company announced Monday. Israel-based, clinical-stage Galmed develops a once-daily oral therapy for liver diseases. The company intends to use the proceeds for clinical and business development and for general corporate purposes. The company's stock jumped around 125% over the past two weeks after it announced a successful study on June 11.

Nasdaq. Photo: Nasdaq Nasdaq. Photo: Nasdaq Nasdaq. Photo: Nasdaq

share on facebook share on twitter share on linkedin share on whatsapp share on mail

TAGS